Should I Buy AME? AME 2026 Analysis

Should You Buy AMETEK Inc (AME) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

231.910

1 Day change

0.92%

52 Week Range

234.560

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: AME is in a strong uptrend with bullish momentum signals and fresh post-earnings / M&A catalysts.
Near-term upside levels: first target is R1 ~230.75, then R2 ~234.94; current price (225.79) is still below most bullish Street targets (230–235+) and well below Deutsche Bank’s 271.
Biggest risk to the buy-now call: it’s extended/near-term overbought (RSI high) and valuation is a stated concern (Oppenheimer downgrade), but the trend + sentiment still favor upside for an impatient entry.

Technical Analysis

Trend: Bullish (SMA_5 > SMA_20 > SMA_200) indicating strong short-, mid-, and long-term upward structure.
Momentum: MACD histogram +0.725 and expanding, confirming accelerating bullish momentum.
RSI: RSI_6 at 76.781 suggests the stock is stretched/overbought short term (more prone to dips), but not a trend-break signal by itself.
Key levels: Pivot support ~223.97 (important “line in the sand”); resistance at R1 ~230.75 then R2 ~234.94; S1 ~217.18 if momentum breaks.
Pattern-based forward bias: modest positive drift indicated (next month ~+2.13% expected move in the pattern set).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios (OI 0.45, volume 0.4) are skewed bullish (more call demand than puts).
Positioning/attention: Today’s option volume is ~~18.16x the 30-day average and open interest is elevated (~~117.51% vs avg), signaling heightened participation.
Volatility: IV_30d ~22.93 vs historical vol ~28.07 implies options are not pricing extreme risk; IV percentile 63.6 = moderately elevated but not “panic high.”

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings beat: Q4 non-GAAP EPS of 2.01 exceeded expectations; revenue around $2.0B with strong YoY growth.
- Event-driven catalyst: Acquisition of LKC Technologies strengthens ophthalmic diagnostics footprint (adds growth adjacency and product depth).
- Macro/industry tailwinds cited by analysts: exposure to short-cycle industrial recovery and AI-related order strength; continued M&A capacity supported by balance sheet strength.

Neutral/Negative Catalysts

- Valuation pushback: Oppenheimer downgraded to Perform explicitly on valuation (market already pricing in growth).
- Near-term technical stretch: RSI suggests the stock can chop/pull back even while remaining in an uptrend.
- Post-market weakness (-1.37%) after the close can create short-term volatility around the earnings/news digestion window.

Financial Performance

Latest quarter: 2025/Q4.
Growth: Revenue $1.998B, +13.44% YoY (strong top-line acceleration).
Profitability: Net income $398.6M, +2.93% YoY; EPS 1.73, +3.59% YoY (bottom-line growth positive but slower than revenue).
Margins: Gross margin 36.93%, +0.90 YoY, indicating improving mix/pricing and operating quality.
Overall read: healthy growth with incremental margin improvement—supports continuation of the uptrend and M&A-driven compounding story.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Multiple upgrades/positive reiterations and higher targets in late Dec–Jan (TD Cowen upgrade to Buy $230; Melius upgrade to Buy $235; KeyBanc Overweight PT to $235; Mizuho Outperform PT to $230; Deutsche Bank initiated Buy $271).
Counterpoint: Oppenheimer downgraded to Perform from Outperform (no PT) citing valuation—this is the primary bearish Street argument.
Wall Street pros: improving short-cycle demand, AI order strength, high backlog, M&A optionality and balance sheet capacity.
Wall Street cons: valuation now reflecting growth; less room for multiple expansion if execution is merely “as expected.”

10 Analyst Rating

Wall Street analysts forecast AME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AME is 231 USD with a low forecast of 210 USD and a high forecast of 246 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 229.790

Low

210

Averages

231

High

246

Current: 229.790

Low

210

Averages

231

High

246

Baird

Neutral

maintain

$204 -> $245

AI Analysis

2026-02-05

New

Reason

Baird

Price Target

$204 -> $245

AI Analysis

2026-02-05

New

maintain

Neutral

Reason

Baird raised the firm's price target on Ametek to $245 from $204 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results as its core growth recovery continues.

Mizuho

Outperform

maintain

$230 -> $235

2026-02-04

New

Reason

Mizuho

Price Target

$230 -> $235

2026-02-04

New

maintain

Outperform

Reason

Mizuho raised the firm's price target on Ametek to $235 from $230 and keeps an Outperform rating on the shares. The company reported strong Q4 results, says the firm, which rising peer valuations for the target boost.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AME

Unlock Now

AME Should I Buy

AME Should I Buy

Should You Buy AMETEK Inc (AME) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch